Skip to main content

Table 1 Patient characteristics at entry

From: Endoscopic sclerotherapy compared with no specific treatment for the primary prevention of bleeding from esophageal varices. A randomized controlled multicentre trial [ISRCTN03215899]

Characteristic Sclerotherapy n = 84 Controls n = 82
Age 56(23–76) 55(20–72)
Sex (M/F) (n) 46/38 49/33
Diagnosis   
   Alcoholic liver disease 41 40
   Hepatitis B/C 24 21
   PBC/PSC 11 8
   Other 24 31
Child-Pugh class A/B/C (n) 44/32/8 47/25/10
Child-Pugh score 6(5–12) 6(5–13)
Esophageal varices   
   grade II 47 42
   grade III 38 40
   grade IV 15 18
Ascites 44 37
Laboratory   
   Bilirubin (μmol/l) 27(7–429) 27(7–217)
   Albumin (g/l) 36(18–48) 35(23–47)
   AT-III (IE/l) 0.7(0.22–1.45) 0.7(0.24–1.32)
   ASAT (U/l) 44.5(12–264) 49(12–373)
  1. Results are expressed as percentages and medians with ranges, unless otherwise indicated. Normal ranges: serum bilirubin <18 μmol/l; albumin > 37 g/l; AT-III 0.85 – 1.50 IE/l; ASAT < 35 U/l